301263 泰恩康
已收盘 09-14 15:00:00
资讯
新帖
简况
泰恩康新提交“-”商标注册申请
证券之星 · 09-11
泰恩康新提交“-”商标注册申请
泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%
证券之星 · 09-02
泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%
泰恩康：和胃整肠丸自7月起开始国产化供货
证券之星 · 08-27
泰恩康：和胃整肠丸自7月起开始国产化供货
泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权
中金财经 · 08-24
泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权
股市必读：泰恩康（301263）8月21日董秘有最新回复
证券之星 · 08-24
股市必读：泰恩康（301263）8月21日董秘有最新回复
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
证券之星 · 08-20
泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准
8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 08-19
8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股
泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债
中金财经 · 08-19
泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债
【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）
证券之星 · 08-19
【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）
泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司
证券之星 · 08-18
泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司
泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%
证券之星 · 08-18
泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%
泰恩康：公司正处于新旧动能转换的业绩拐点期
证券之星 · 08-18
泰恩康：公司正处于新旧动能转换的业绩拐点期
图解泰恩康中报：第二季度单季净利润同比下降548.88%
证券之星 · 08-18
图解泰恩康中报：第二季度单季净利润同比下降548.88%
泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益
格隆汇 · 08-17
泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益
泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%
证券之星 · 08-10
泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%
股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》
证券之星 · 08-10
股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》
泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采
格隆汇 · 08-07
泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采
8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股
证券之星 · 08-07
8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股
股市必读：泰恩康新发布《关于回购公司股份的进展公告》
证券之星 · 08-04
股市必读：泰恩康新发布《关于回购公司股份的进展公告》
7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股
证券之星 · 07-17
7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股
加载更多
公司概况
公司名称：
广东泰恩康医药股份有限公司
所属行业：
批发业
上市日期：
2022-03-29
主营业务：
广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。
发行价格：
19.93
{"stockData":{"symbol":"301263","market":"SZ","secType":"STK","nameCN":"泰恩康","latestPrice":20.52,"timestamp":1789369395000,"preClose":19.75,"halted":0,"volume":5197949,"delay":0,"changeRate":0.039,"floatShares":364000000,"shares":511000000,"eps":-0.0093,"marketStatus":"已收盘","change":0.77,"latestTime":"09-14 15:00:00","open":19.72,"high":20.68,"low":19.44,"amount":105000000,"amplitude":0.0628,"askPrice":20.52,"askSize":31,"bidPrice":20.5,"bidSize":15,"shortable":0,"etf":0,"ttmEps":-0.0093,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":5,"adr":0,"adjPreClose":19.75,"symbolType":"stock","openAndCloseTimeList":[[1789349400000,1789356600000],[1789362000000,1789369200000]],"highLimit":21.73,"lowLimit":17.78,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":510597000,"isCdr":false,"pbRate":6.11,"roa":"--","roe":"0.22%","epsLYR":0.07,"committee":-0.575758,"marketValue":10477000000,"turnoverRate":0.0143,"status":0,"floatMarketCap":7476000000},"requestUrl":"/m/hq/s/301263","defaultTab":"news","newsList":[{"id":"2666118505","title":"泰恩康新提交“-”商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2666118505","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666118505?lang=zh_cn&edition=full","pubTime":"2026-09-11 07:15","pubTimestamp":1789082115,"startTime":"0","endTime":"0","summary":"证券之星消息，根据天眼查APP数据显示，近日广东泰恩康医药股份有限公司新提交“-”商标注册申请。商标申请详情如下：今年以来广东泰恩康医药股份有限公司新申请注册商标17件，截止目前公司共持有注册商标529件，另有115件商标尚在注册申请中。结合公司2026年中报财务数据，今年上半年公司在研发方面投入了3051.88万元，同比减10.13%。通过天眼查大数据分析，广东泰恩康医药股份有限公司共对外投资了11家企业，参与招投标项目7次；财产线索方面有商标信息497条，专利信息5条，著作权信息3条；此外企业还拥有行政许可308个。数据来源：天眼查APP以上内容为证券之星据公开信息整理，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091100013377.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664381081","title":"泰恩康（301263）披露回购公司股份进展公告，9月2日股价下跌2.81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2664381081","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664381081?lang=zh_cn&edition=full","pubTime":"2026-09-02 22:37","pubTimestamp":1788359832,"startTime":"0","endTime":"0","summary":"截至2026年9月2日收盘，泰恩康报收于19.02元，较前一交易日下跌2.81%，最新总市值为97.12亿元。公司于2026年9月2日披露《关于回购公司股份的进展公告》。公告显示，广东泰恩康医药股份有限公司于2026年6月16日召开董事会，审议通过回购公司股份方案，拟使用自有及自筹资金通过集中竞价方式回购A股股份，用于维护公司价值及股东权益。本次回购符合相关法规及公司方案要求。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090200043115.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662700360","title":"泰恩康：和胃整肠丸自7月起开始国产化供货","url":"https://stock-news.laohu8.com/highlight/detail?id=2662700360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662700360?lang=zh_cn&edition=full","pubTime":"2026-08-27 20:48","pubTimestamp":1787834897,"startTime":"0","endTime":"0","summary":"和胃整肠丸7月份开始供货，是否会对三季度业绩造成影响？和胃整肠丸是公司成熟胃药大品种，将为三季度带来积极的业绩增量贡献，具体销售情况请关注公司后续定期报告。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082700051149.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661099242","title":"泰恩康与普罗凯融签署协议 锁定MSCohi-O镜片中国独家推广权","url":"https://stock-news.laohu8.com/highlight/detail?id=2661099242","media":"中金财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661099242?lang=zh_cn&edition=full","pubTime":"2026-08-24 10:27","pubTimestamp":1787538424,"startTime":"0","endTime":"0","summary":"8月17日晚间，泰恩康对外发布签署《战略合作协议》的自愿性披露公告。公告显示，近日公司已与广东普罗凯融生物医药科技有限公司及其实际控制人签署了《战略合作协议》。在泰恩康按照《增资协议》约定足额支付增资认购款并完成本次股权投资交割的前提下，泰恩康将取得MSCohi-O镜片项目在中国区域的独家商业推广服务权益。企业方面表示，MSCohi-O镜片是全球首创眼科眼表干细胞创新疗法，适应症拓展空间巨大，符合未来治疗趋势。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260824/32344313.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661324575","title":"股市必读：泰恩康（301263）8月21日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2661324575","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661324575?lang=zh_cn&edition=full","pubTime":"2026-08-24 04:07","pubTimestamp":1787515631,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，泰恩康报收于19.03元，下跌4.03%，换手率1.49%，成交量5.42万手，成交额1.04亿元。董秘最新回复投资者： 1、贵公司从3季度开始经营情况将逐步向好，但是从市场走势来看始终有资金不想贵公司股价上涨关键原因是没有利用好回购资金走出强势走势打出辨识度？当日关注点交易信息汇总：8月21日主力资金净流入334.24万元，占总成交额3.21%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082400001582.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660288738","title":"泰恩康最新公告：全资子公司注射用顺铂聚合物胶束获临床试验批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2660288738","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660288738?lang=zh_cn&edition=full","pubTime":"2026-08-20 17:55","pubTimestamp":1787219730,"startTime":"0","endTime":"0","summary":"泰恩康(301263.SZ)公告称，公司全资子公司华铂凯盛收到国家药监局签发的《药物临床试验批准通知书》，同意注射用顺铂聚合物胶束单药在晚期恶性肿瘤中开展临床试验。该药品为化药2.2类，旨在降低顺铂毒副作用并实现被动靶向性。目前国内尚无该药品获注册批件，公司提示研发及上市存在不确定性风险。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082000032566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660449641","title":"8月19日泰恩康跌5.02%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2660449641","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660449641?lang=zh_cn&edition=full","pubTime":"2026-08-19 17:16","pubTimestamp":1787130962,"startTime":"0","endTime":"0","summary":"证券之星消息，8月19日泰恩康跌5.02%，收盘报19.67元，换手率2.16%，成交量7.87万手，成交额1.58亿元。根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900029686.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660411584","title":"泰恩康H1净利降9成 A股募11.8亿国泰海通保荐拟发可转债","url":"https://stock-news.laohu8.com/highlight/detail?id=2660411584","media":"中金财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660411584?lang=zh_cn&edition=full","pubTime":"2026-08-19 11:32","pubTimestamp":1787110322,"startTime":"0","endTime":"0","summary":"中国经济网北京8月19日讯 泰恩康 近日披露2026年半年度报告。今年上半年，公司实现营业收入3.20亿元，同比下降7.72%；归属于上市公司股东的净利润为372.02万元，同比下降89.97%；归属于上市公司股东的扣非净利润为29.06万元，同比下降99.21%；经营活动产生的现金流量净额为5427.15万元，上年同期为-4037.98万元。 泰恩康本次发行费用总额为1.26亿元，其中保荐机构国泰君安证券获得保荐及承销费用1.02亿元。","market":"fut","thumbnail":" http://caiji.3g.cnfol.com/colect/202608/19/20260819574245.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202608/19/20260819574245.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushijujiao/20260819/32339545.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0276","BK1147","02827","03130","07233","SABA","BK0201","03188","BK0012","BK0183","399300","BK0184","82846","02611","159982","BK0188","02846","301263","BK1564","83130","BK0250","BK0028","601211","83188","FCEF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660187264","title":"【机构调研记录】申万菱信基金调研泰恩康、盛美上海等3只个股（附名单）","url":"https://stock-news.laohu8.com/highlight/detail?id=2660187264","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660187264?lang=zh_cn&edition=full","pubTime":"2026-08-19 08:14","pubTimestamp":1787098484,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息及8月18日披露的机构调研信息，申万菱信基金近期对3家上市公司进行了调研，相关名单如下：1）泰恩康 调研纪要：MSCohi-O镜片2026年7月完成I期临床，进入IIa期，预计2027年完成IIb期后提交附条件上市申请。2）盛美上海 调研纪要：公司与海力士保持良好合作，相关进展达标后将披露。旗下最近一年表现最佳的公募基金产品为申万菱信智能驱动股票A，最新单位净值为10.03，近一年增长168.79%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900006988.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","301263","BK0250","688082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660360466","title":"泰恩康：华创证券、国泰海通华源证券等多家机构于8月18日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2660360466","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660360466?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:40","pubTimestamp":1787046058,"startTime":"0","endTime":"0","summary":"MSCohi-O镜片于 2023年 5月获 FD 孤儿药资格认定，成为全球第一款针对治疗眼部移植物抗宿主病被 FD认定孤儿药的药物。同时，无药物相关的严重不良反应发生，患者依从性高，显示优异的安全性。MSCohi-O 镜片现有适应症及后续拓展新适应症的合计销售峰值预计 15亿元以上。②预计盐酸毛果芸香碱滴眼液、利多卡因丙胺卡因气雾剂将于 2027年获批，有望实现快速放量，将成为公司重要增长动力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800031471.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601211","BK1564","BK0183","BK0188","BK1147","02611","BK0184","BK0250","BK0012","BK0276","161027","BK0028","BK0201","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660346547","title":"泰恩康(301263)6月30日股东户数1.47万户，较上期增加12.93%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660346547","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660346547?lang=zh_cn&edition=full","pubTime":"2026-08-18 17:31","pubTimestamp":1787045492,"startTime":"0","endTime":"0","summary":"证券之星消息，近日泰恩康披露，截至2026年6月30日公司股东户数为1.47万户，较3月31日增加1680.0户，增幅为12.93%。在化学制药行业个股中，泰恩康股东户数低于行业平均水平，截至6月30日，化学制药行业平均股东户数为3.64万户。从股价来看，2026年3月31日至2026年6月30日，泰恩康区间跌幅为4.66%，在此期间股东户数增加1680.0户，增幅为12.93%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800030787.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660463943","title":"泰恩康：公司正处于新旧动能转换的业绩拐点期","url":"https://stock-news.laohu8.com/highlight/detail?id=2660463943","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660463943?lang=zh_cn&edition=full","pubTime":"2026-08-18 16:54","pubTimestamp":1787043248,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康08月18日在投资者关系平台上答复投资者关心的问题。泰恩康回复：尊敬的投资者朋友您好，针对您提出的问题回复如下：1、公司后续若拟召开业绩说明会将及时履行信息披露义务，请您留意公司在巨潮资讯网披露的相关公告。公司管理层将积极争取实现2026年股权激励的收入考核目标。感谢您对公司的关注。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800028962.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660431558","title":"图解泰恩康中报：第二季度单季净利润同比下降548.88%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660431558","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660431558?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:31","pubTimestamp":1786987909,"startTime":"0","endTime":"0","summary":"证券之星消息，泰恩康2026年中报显示，上半年度公司主营收入3.2亿元，同比下降7.72%；归母净利润372.02万元，同比下降89.97%；扣非净利润29.06万元，同比下降99.21%；其中2026年第二季度，公司单季度主营收入1.31亿元，同比下降19.49%；单季度归母净利润-2486.27万元，同比下降548.88%；单季度扣非净利润-2745.34万元，同比下降606.23%；负债率32.35%，投资收益334.79万元，财务费用448.48万元，毛利率56.14%。财报数据概要请见下图:本文数据来源于泰恩康2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660248284","title":"泰恩康：签署战略合作协议获MSCohi-O镜片项目独家商业推广权益","url":"https://stock-news.laohu8.com/highlight/detail?id=2660248284","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660248284?lang=zh_cn&edition=full","pubTime":"2026-08-17 19:31","pubTimestamp":1786966277,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658898237","title":"泰恩康（301263）披露全资子公司巴瑞替尼片中选第十二批国家药品集采，8月10日股价上涨1.64%","url":"https://stock-news.laohu8.com/highlight/detail?id=2658898237","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658898237?lang=zh_cn&edition=full","pubTime":"2026-08-10 17:42","pubTimestamp":1786354962,"startTime":"0","endTime":"0","summary":"截至2026年8月10日收盘，泰恩康报收于21.75元，较前一交易日上涨1.64%，最新总市值为111.05亿元。该股当日开盘21.48元，最高22.58元，最低21.48元，成交额达1.52亿元，换手率为1.9%。近日，泰恩康发布《关于全资子公司部分药品中选国家药品集中采购的公告》。公告指出，中选后有望促进该产品销售放量和市场拓展，提升公司品牌影响力，对经营业绩产生积极影响；后续采购协议签订及业绩影响存在不确定性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000023012.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2658608631","title":"股市必读：泰恩康新发布《关于全资子公司部分药品中选国家药品集中采购的公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2658608631","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2658608631?lang=zh_cn&edition=full","pubTime":"2026-08-10 02:39","pubTimestamp":1786300750,"startTime":"0","endTime":"0","summary":"交易信息汇总资金流向8月7日主力资金净流出185.7万元，占总成交额1.02%；游资资金净流出303.09万元，占总成交额1.66%；散户资金净流入488.79万元，占总成交额2.67%。中选后有望促进该产品销售放量和市场拓展，提升公司品牌影响力，对经营业绩产生积极影响。后续采购协议签订及业绩影响存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081000001140.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0250","301263"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657161110","title":"泰恩康：全资子公司巴瑞替尼片中选第十二批国家药品集采","url":"https://stock-news.laohu8.com/highlight/detail?id=2657161110","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657161110?lang=zh_cn&edition=full","pubTime":"2026-08-07 17:42","pubTimestamp":1786095749,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657616195","title":"8月7日泰恩康涨6.31%，前海开源优质龙头6个月持有混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2657616195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2657616195?lang=zh_cn&edition=full","pubTime":"2026-08-07 16:51","pubTimestamp":1786092660,"startTime":"0","endTime":"0","summary":"根据2026基金半年报公募基金重仓股数据，重仓该股的公募基金共2家，其中持有数量最多的公募基金为前海开源基金的前海开源优质龙头6个月持有混合A。前海开源优质龙头6个月持有混合A目前规模为3.6亿元，最新净值0.6749，较上一交易日下跌1.08%，近一年下跌7.5%。前海开源优质龙头6个月持有混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080700028243.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656055733","title":"股市必读：泰恩康新发布《关于回购公司股份的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656055733","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656055733?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:36","pubTimestamp":1785778573,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，泰恩康报收于20.14元，下跌1.71%，换手率1.32%，成交量4.82万手，成交额9755.49万元。公司公告汇总：截至7月31日，泰恩康已累计回购股份2,434,400股，占总股本0.4768%，支付资金总额48,442,397.06元。公司公告汇总关于回购公司股份的进展公告广东泰恩康医药股份有限公司于2026年6月16日召开董事会，审议通过回购公司股份方案，拟使用自有及自筹资金以集中竞价方式回购A股股份，用于维护公司价值及股东权益。本次回购符合相关法规及公司方案规定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652409681","title":"7月17日泰恩康跌11.14%，大成积极成长混合A基金重仓该股","url":"https://stock-news.laohu8.com/highlight/detail?id=2652409681","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2652409681?lang=zh_cn&edition=full","pubTime":"2026-07-17 17:01","pubTimestamp":1784278871,"startTime":"0","endTime":"0","summary":"证券之星消息，7月17日泰恩康跌11.14%，收盘报19.3元，换手率2.95%，成交量10.76万手，成交额2.17亿元。根据2026基金Q1季报公募基金重仓股数据，重仓该股的公募基金共4家，其中持有数量最多的公募基金为大成基金的大成积极成长混合A。大成积极成长混合A目前规模为9.3亿元，最新净值1.151，较上一交易日下跌1.37%，近一年上涨29.47%。大成积极成长混合A的前十大重仓股如下：以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026071700030854.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["301263","BK0250"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1789408649724,"stockEarnings":[{"period":"1week","weight":0.0234},{"period":"1month","weight":-0.0063},{"period":"3month","weight":0.0406},{"period":"6month","weight":-0.0995},{"period":"1year","weight":-0.326},{"period":"ytd","weight":-0.1489}],"compareEarnings":[{"period":"1week","weight":-0.012},{"period":"1month","weight":-0.0107},{"period":"3month","weight":-0.0505},{"period":"6month","weight":-0.0437},{"period":"1year","weight":0.0038},{"period":"ytd","weight":-0.021}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"广东泰恩康医药股份有限公司","boardCode":"AI0051","boardName":"批发业","stockholders":"14676人(较上一季度增加12.93%)","perCapita":"24823股","listingDate":"2022-03-29","address":"广东省汕头市龙湖区泰山北路万吉南二街8号A幢","registeredCapital":"51059万元","survey":" 广东泰恩康医药股份有限公司的主营业务是代理运营及研发、生产、销售医药产品、医疗器械、卫生材料并提供医药技术服务与技术转让等。公司的主要产品是盐酸达泊西汀片、他达拉非片、枸橼酸西地那非口崩片、和胃整肠丸、沃丽汀、风油精、六味地黄丸、藿香正气丸、奥硝唑注射液。","listedPrice":19.93},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"泰恩康,301263,泰恩康股票,泰恩康股票老虎,泰恩康股票老虎国际,泰恩康行情,泰恩康股票行情,泰恩康股价,泰恩康股市,泰恩康股票价格,泰恩康股票交易,泰恩康股票购买,泰恩康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"泰恩康(301263)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供泰恩康(301263)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}